Investing.com - CytomX Therapeutics Inc (NASDAQ: CTMX) reported first quarter EPS of $-0.080, $0.03 worse than the analyst estimate of $-0.050. Revenue for the quarter came in at $26.6M versus the consensus estimate of $19.6M.
CytomX Therapeutics Inc's stock price closed at $2.510. It is up 70.750% in the last 3 months and up 34.950% in the last 12 months.
CytomX Therapeutics Inc saw 6 positive EPS revisions and 0 negative EPS revisions in the last 90 days. See CytomX Therapeutics Inc's stock price’s past reactions to earnings here.
According to InvestingPro, CytomX Therapeutics Inc's Financial Health score is "good performance".
Check out CytomX Therapeutics Inc's recent earnings performance, and CytomX Therapeutics Inc's financials here.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar